A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter

Kelsie M. LaBarbera; Yvette I. Sheline; Nicholas J. Izzo; Carla M. Yuede; Lora Waybright; Raymond Yurko; Hannah M. Edwards; Woodrow D. Gardiner; Kaj Blennow; Henrik Zetterberg; Anne Börjesson-Hanson; Roger Morgan; Charles S. Davis; Robert J. Guttendorf; Lon S. Schneider; Steven DeKosky; Harry LeVine; Michael Grundman; Anthony O. Caggiano; John R. Cirrito; Susan M. Catalano; Mary E. Hamby

doi:10.1186/s40035-023-00358-w

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter

Kelsie M. LaBarbera, Yvette I. Sheline, Nicholas J. Izzo, Carla M. Yuede, Lora Waybright, Raymond Yurko, Hannah M. Edwards, Woodrow D. Gardiner, Kaj Blennow, Henrik Zetterberg, Anne Börjesson-Hanson, Roger Morgan, Charles S. Davis, Robert J. Guttendorf, Lon S. Schneider, Steven DeKosky, Harry LeVine, Michael Grundman, Anthony O. Caggiano, John R. CirritoSusan M. Catalano, Mary E. Hamby

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English
Article number	24
Journal	Translational Neurodegeneration
Volume	12
Issue number	1
DOIs	https://doi.org/10.1186/s40035-023-00358-w
State	Published - Dec 2023

Access to Document

10.1186/s40035-023-00358-w

Cite this

LaBarbera, K. M., Sheline, Y. I., Izzo, N. J., Yuede, C. M., Waybright, L., Yurko, R., Edwards, H. M., Gardiner, W. D., Blennow, K., Zetterberg, H., Börjesson-Hanson, A., Morgan, R., Davis, C. S., Guttendorf, R. J., Schneider, L. S., DeKosky, S., LeVine, H., Grundman, M., Caggiano, A. O., ... Hamby, M. E. (2023). A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter. Translational Neurodegeneration, 12(1), Article 24. https://doi.org/10.1186/s40035-023-00358-w

@article{99a2ab5dcab8426fb7ab5ab9eecf8f7d,

title = "A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer{\textquoteright}s disease using an indwelling CSF catheter",

author = "LaBarbera, {Kelsie M.} and Sheline, {Yvette I.} and Izzo, {Nicholas J.} and Yuede, {Carla M.} and Lora Waybright and Raymond Yurko and Edwards, {Hannah M.} and Gardiner, {Woodrow D.} and Kaj Blennow and Henrik Zetterberg and Anne B{\"o}rjesson-Hanson and Roger Morgan and Davis, {Charles S.} and Guttendorf, {Robert J.} and Schneider, {Lon S.} and Steven DeKosky and Harry LeVine and Michael Grundman and Caggiano, {Anthony O.} and Cirrito, {John R.} and Catalano, {Susan M.} and Hamby, {Mary E.}",

note = "Funding Information: This work was supported by grants from the National Institute on Aging (AG057780 to SMC) and by Cognition Therapeutics, Inc. Content is solely the authors{\textquoteright} and does not represent the National Institutes of Health. Funding Information: Current/former employees of Cognition Therapeutics (Cognition): NJI, KML, RY, LW, MEH, SMC, AOC. Cognition paid consultants: CMY, JRC, RJG, CSD, MG, RM. LSS grants/fees: Eli Lilly, Merck, Roche/Genentech, Avraham, Boehringer Ingelheim, Neurim, Neuronix, Cognition, Eisai, Takeda, vTv, Abbott, Biogen, Novartis, Biohaven, outside this work. SD Chair of: Acumen Medical Scientific Advisory Board, Biogen Drug Monitoring Committee, Cognition Medical Advisory Board, DSMB for Prevail Pharmaceuticals and for pepinemab (Vaccinex, Inc.), Associate Editor of Neurotherapeutics, Editor for Dementia for UpToDate. HZ: SABs/as consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognition, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, Roche, is co-founder of Brain Biomarker Solutions (BBS, of GU Ventures Incubator; outside this work). KB: consultant, advisory boards, data monitoring committees Abcam, Axon, Biogen, Cognition, Julius Clinical, Lilly, MagQu, Novartis, Siemens Healthineers, Roche Diagnostics, is co-founder of BBS. International Patent WO 15/116923 pertains to this paper. YIS received a grant to the University of Pennsylvania supporting this research. ABH has lectured or served at SABs for Abbvie, Alector, BioArctic, Biogen, Eisai, Janssen, Novo Nordisk, Roche.",

year = "2023",

month = dec,

doi = "10.1186/s40035-023-00358-w",

language = "English",

volume = "12",

journal = "Translational Neurodegeneration",

issn = "2047-9158",

number = "1",

}

LaBarbera, KM, Sheline, YI, Izzo, NJ, Yuede, CM, Waybright, L, Yurko, R, Edwards, HM, Gardiner, WD, Blennow, K, Zetterberg, H, Börjesson-Hanson, A, Morgan, R, Davis, CS, Guttendorf, RJ, Schneider, LS, DeKosky, S, LeVine, H, Grundman, M, Caggiano, AO, Cirrito, JR, Catalano, SM & Hamby, ME 2023, 'A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter', Translational Neurodegeneration, vol. 12, no. 1, 24. https://doi.org/10.1186/s40035-023-00358-w

TY - JOUR

T1 - A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter

AU - LaBarbera, Kelsie M.

AU - Sheline, Yvette I.

AU - Izzo, Nicholas J.

AU - Yuede, Carla M.

AU - Waybright, Lora

AU - Yurko, Raymond

AU - Edwards, Hannah M.

AU - Gardiner, Woodrow D.

AU - Blennow, Kaj

AU - Zetterberg, Henrik

AU - Börjesson-Hanson, Anne

AU - Morgan, Roger

AU - Davis, Charles S.

AU - Guttendorf, Robert J.

AU - Schneider, Lon S.

AU - DeKosky, Steven

AU - LeVine, Harry

AU - Grundman, Michael

AU - Caggiano, Anthony O.

AU - Cirrito, John R.

AU - Catalano, Susan M.

AU - Hamby, Mary E.

N1 - Funding Information: This work was supported by grants from the National Institute on Aging (AG057780 to SMC) and by Cognition Therapeutics, Inc. Content is solely the authors’ and does not represent the National Institutes of Health. Funding Information: Current/former employees of Cognition Therapeutics (Cognition): NJI, KML, RY, LW, MEH, SMC, AOC. Cognition paid consultants: CMY, JRC, RJG, CSD, MG, RM. LSS grants/fees: Eli Lilly, Merck, Roche/Genentech, Avraham, Boehringer Ingelheim, Neurim, Neuronix, Cognition, Eisai, Takeda, vTv, Abbott, Biogen, Novartis, Biohaven, outside this work. SD Chair of: Acumen Medical Scientific Advisory Board, Biogen Drug Monitoring Committee, Cognition Medical Advisory Board, DSMB for Prevail Pharmaceuticals and for pepinemab (Vaccinex, Inc.), Associate Editor of Neurotherapeutics, Editor for Dementia for UpToDate. HZ: SABs/as consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognition, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, Roche, is co-founder of Brain Biomarker Solutions (BBS, of GU Ventures Incubator; outside this work). KB: consultant, advisory boards, data monitoring committees Abcam, Axon, Biogen, Cognition, Julius Clinical, Lilly, MagQu, Novartis, Siemens Healthineers, Roche Diagnostics, is co-founder of BBS. International Patent WO 15/116923 pertains to this paper. YIS received a grant to the University of Pennsylvania supporting this research. ABH has lectured or served at SABs for Abbvie, Alector, BioArctic, Biogen, Eisai, Janssen, Novo Nordisk, Roche.

PY - 2023/12

Y1 - 2023/12

UR - http://www.scopus.com/inward/record.url?scp=85159937767&partnerID=8YFLogxK

U2 - 10.1186/s40035-023-00358-w

DO - 10.1186/s40035-023-00358-w

M3 - Letter

C2 - 37173791

AN - SCOPUS:85159937767

SN - 2047-9158

VL - 12

JO - Translational Neurodegeneration

JF - Translational Neurodegeneration

IS - 1

M1 - 24

ER -

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter

Access to Document

Other files and links

Cite this